{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:23Z","timestamp":1772165783631,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Beh\u00e7et\u2019s disease (BD) is a chronic, relapsing, systemic vasculitis that can involve both arteries and veins. Ocular involvement, including non-granulomatous panuveitis and occlusive retinal vasculitis, is common and a significant cause of morbidity. Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor approved for migraine prevention Although it is generally well tolerated, recent concerns have emerged regarding its vasoconstrictive potential in patients with underlying vascular disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 44-year-old woman with a history of BD, well-managed with azathioprine and methotrexate, who developed painless, bilateral subacute visual loss eleven days after receiving her second monthly dose of erenumab. This occurred during a BD flare marked by oral ulcers and severe migraine. Despite corticosteroid treatment, visual acuity did not improve. Erenumab was discontinued, but at her following visit four weeks later, vision remained impaired and visual fields showed blind spot enlargement and nonspecific defects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We hypothesize that the patient\u2019s visual loss was due to secondary ischemia from BD\u2013associated small-vessel vasculitis, potentially exacerbated by CGRP receptor blockade from erenumab, which may have impaired compensatory vasodilation in the optic nerve or retinal circulation. This case represents the first report of permanent bilateral visual impairment associated with CGRP antagonist use in a patient with BD. Recent FDA labeling updates for CGRP-targeting agents now caution against use in patients with preexisting vascular disease, including risk of hypertension and Raynaud\u2019s phenomenon. This case underscores the need for heightened caution when prescribing CGRP inhibitors to patients with systemic vasculitic disorders and highlights the importance of further investigation to better define the safety profile of these agents in individuals with underlying vascular disease.\u00a0<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04322-2","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:10:50Z","timestamp":1759230650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Permanent visual impairment following a Beh\u00e7et\u2019s disease flare while on calcitonin gene-related peptide receptor antagonist therapy: a case report"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-5004","authenticated-orcid":false,"given":"Fawad A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Fahimdanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmveer","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Elison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"4322_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, Yazici Y. Beh\u00e7et syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107\u201319.","journal-title":"Nat Rev Rheumatol"},{"key":"4322_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Beh\u00e7et\u2019s disease: An international collaborative study. British Journal of Ophthalmology. 2007;91:1579\u201382.","journal-title":"British Journal of Ophthalmology"},{"key":"4322_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1526-4610.2007.01041.x","volume":"48","author":"AB Haghighi","year":"2008","unstructured":"Haghighi AB, Aflaki E, Ketabchi L. The prevalence and characteristics of different types of headache in beh\u00e7et\u2019s disease: A case-control study. Headache. 2008;48:424\u20139.","journal-title":"Headache"},{"key":"4322_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache. 2024;64:333\u201341.","journal-title":"Headache"},{"key":"4322_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40261-022-01230-x","volume":"43","author":"FF Bomtempo","year":"2023","unstructured":"Bomtempo FF, Rocha RB, Cenci GI, Nager GB, Telles JPM. Long-Term safety and effectiveness of erenumab in patients with migraine: A systematic review and Single-Arm Meta-analysis. Clin Drug Investig. 2023;43:45\u201359.","journal-title":"Clin Drug Investig"},{"key":"4322_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"MaassenVanDenBrink A, Meijer J, Villal\u00f3n CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779\u201388.","journal-title":"Trends Pharmacol Sci"},{"key":"4322_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01330-7","volume":"22","author":"JC Ray","year":"2021","unstructured":"Ray JC, Allen P, Bacsi A, Bosco JJ, Chen L, Eller M, Kua H, Lim LL, Matharu MS, Monif M, Ruttledge M, Stark RJ, Hutton EJ. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22:1\u20138.","journal-title":"J Headache Pain"},{"key":"4322_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K. Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review. J Headache Pain. 2023;24:99.","journal-title":"J Headache Pain"},{"key":"4322_CR9","first-page":"42","volume":"35","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Liston HL. An explanation of the second-dose effect in pharmacokinetics and its meaning for clinical psychopharmacology. Psychopharmacol Bull. 2001;35:42\u201352.","journal-title":"Psychopharmacol Bull"},{"key":"4322_CR10","unstructured":"Drug Safety-related Labeling Changes (SrLC). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm Accessed May 25, 2025."},{"issue":"2","key":"4322_CR11","doi-asserted-by":"publisher","first-page":"333102422114353","DOI":"10.1177\/03331024221143538","volume":"43","author":"M Ruiz","year":"2023","unstructured":"Ruiz M, Cocores A, Tosti A, et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases series, evaluation of FAERS, and literature review. Cephalalgia. 2023;43(2):3331024221143538.","journal-title":"Cephalalgia"},{"issue":"2","key":"4322_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14740338.2023.2248877","volume":"23","author":"R Singh","year":"2024","unstructured":"Singh R, Kumar A, Lather V, et al. Identification of novel signal of raynaud\u2019s phenomenon with calcitonin gene-related peptide(CGRP) antagonists using data mining algorithms and network Pharmacological approaches. Expert Opin Drug Saf. 2024;23(2):231\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"4322_CR13","doi-asserted-by":"publisher","first-page":"e213852","DOI":"10.1212\/WNL.0000000000213852","volume":"105","author":"MT Eller","year":"2025","unstructured":"Eller MT, Schwarzov\u00e1 K, Gufler L, Karisik A, Kaltseis K, Frank F, Broessner G. CGRP-Targeted migraine therapies in patients with vascular risk factors or stroke: A review. Neurology. 2025;105(2):e213852.","journal-title":"Neurology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04322-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:10:55Z","timestamp":1759230655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4322"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04322-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6961004\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval \u2013 This case report was approved by Ochsner Neuroscience Research Review Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication, including the use of clinical details and clinical images, was obtained from the patient discussed in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fawad A. Khan reported receiving institutional research support from Biohaven, Teva, Marinus, Lundbeck, Supernus, Neurona, and UCB; advisory fees from Eisai, Neurelis, Marinus, Epitel, SK Life Science, AbbVie, Pfizer; honorarium for speaker engagements from Amgen, UCB, SK Life Science, Lundbeck, Abbvie, Lilly USA, Pfizer. He serves on the Louisiana State Medical Advisory Board in a non-paid position. In non-compensated roles, he is a board member of the Deccan Alumni Association of North America. Alaa Malik, Evan Nelson, Kian Fahimdanesh, Karmveer Kaur, Jasmine Elison, Mohamed Sayed report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"518"}}